Immunocore Holdings PLC - ESG Rating & Company Profile powered by AI
The webpage displays a free E,S&G assessment for Immunocore Holdings PLC. Full ESG analysis of Immunocore Holdings PLC can be reached by signing up for free. If you work at Immunocore Holdings PLC and you wish to use your Sustainability aseessment, please contact us.
Immunocore Holdings PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 8.0, social score of 4.8 and governance score of 3.2.
5.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 645 | Biomm SA | 5.4 | High |
| 645 | Tiziana Life Sciences PLC | 5.4 | High |
| 658 | Immunocore Holdings PLC | 5.3 | High |
| 658 | Cellmid Ltd | 5.3 | High |
| 658 | Bio-Techne Corp | 5.3 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Immunocore Holdings PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Immunocore Holdings PLC report the average age of the workforce?
Sign up for free to unlockDoes Immunocore Holdings PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Immunocore Holdings PLC offer flexible work?
Sign up for free to unlockDoes Immunocore Holdings PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Immunocore Holdings PLC conduct supply chain audits?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Immunocore Holdings PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose water use targets?
Sign up for free to unlockDoes Immunocore Holdings PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Immunocore Holdings PLC have a product recall in the last two years?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Immunocore Holdings PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Immunocore Holdings PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose parental leave metrics?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Immunocore Holdings PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Immunocore Holdings PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Immunocore Holdings PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose its waste policy?
Sign up for free to unlockDoes Immunocore Holdings PLC report according to TCFD requirements?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose energy use targets?
Sign up for free to unlockDoes Immunocore Holdings PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Immunocore Holdings PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Immunocore Holdings PLC
These potential risks are based on the size, segment and geographies of the company.
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.